Rethinking treatment strategies for idiopathic pulmonary fibrosis: Reevaluation of anti-inflammatory and immunosuppressive therapies

Masashi Bando

doi:10.1016/j.resinv.2022.10.007

Rethinking treatment strategies for idiopathic pulmonary fibrosis: Reevaluation of anti-inflammatory and immunosuppressive therapies

Respir Investig. 2023 Jan;61(1):58-60. doi: 10.1016/j.resinv.2022.10.007. Epub 2022 Nov 30.

Author

Masashi Bando¹

Affiliation

¹ Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke, Tochigi, 320-0498, Japan. Electronic address: [email protected].

PMID: 36460586
DOI: 10.1016/j.resinv.2022.10.007

No abstract available

Keywords: Anti-inflammatory and immunosuppressive therapies; Antifibrotic therapy; Combination therapy; Idiopathic pulmonary fibrosis (IPF); Immunopathogenesis.

Publication types

Editorial

MeSH terms

Anti-Inflammatory Agents / therapeutic use
Humans
Idiopathic Pulmonary Fibrosis* / drug therapy
Immunosuppression Therapy
Pyridones / therapeutic use

Substances

Anti-Inflammatory Agents
Pyridones